- NEWS IN BRIEF
GSK’s first-in-class antibiotic secures another phase III win, approaches regulatory run
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature Reviews Drug Discovery 23, 239 (2024)
doi: https://doi.org/10.1038/d41573-024-00047-x